文献速递治疗药物监测与药物基因组学特殊人群用药抗菌药物管理

新生儿万古霉素治疗药物监测的贝叶斯模型选择

Bayesian Vancomycin Model Selection for Therapeutic Drug Monitoring in Neonates.
PubMed 文献 · Clin Pharmacokinet · 2024-02-28

本研究在69名新生儿中评估已发表万古霉素群体药代动力学模型的预测性能,采用MAE、rBias和rRMSE量化准确性,发现仅De Cock等2014年模型在先验、后验及贝叶斯预测下均临床可接受,建议用于个体化 dosing。

要点

  • De Cock 2014模型在新生儿万古霉素TDM中预测性能最佳。
  • 临床可接受标准为rBias在±20%内且95%CI包含零。
  • 贝叶斯预测下一疗程时该模型仍满足临床可接受标准。

核心结论

  • De Cock等2014年模型是唯一在先验、后验和贝叶斯预测下一疗程三种方法下均临床可接受的模型,可用于该院新生儿万古霉素个体化给药。

研究设计与样本

  • 基于当地69名新生儿队列,在Tucuxi软件中评估9个筛选出的万古霉素群体药代动力学模型的预测性能。

主要发现

  • 先验法:De Cock模型MAE 0.35 mg/L,rBias 0.8%(95%CI -7.5, 9.1%),rRMSE 8.9%。
  • 后验法:MAE 0.037 mg/L,rBias -0.23%(95%CI -1.3, 0.88%),rRMSE 6.02%。
  • 贝叶斯预测下一疗程:MAE 0.89 mg/L,rBias 5.45%(95%CI -8.2, 19.1%),rRMSE 38.3%。

关键数值与推荐

  • 模型临床可接受定义为rBias在±20%之间且95%置信区间包含零。

临床怎么用

  • 在该院新生儿中可选用De Cock 2014模型进行万古霉素贝叶斯治疗药物监测和个体化剂量调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Pharmacokinetic models can inform drug dosing of vancomycin in neonates to optimize therapy. However, the model selected needs to describe the intended population to provide appropriate dose recommendations. Our study aims to identify the population pharmacokinetic (PopPK) model(s) with the best performance to predict vancomycin exposure in neonates in our hospital. METHODS: Relevant published PopPK models for vancomycin in neonates were selected based on demographics and vancomycin dosing strategy. The predictive performance of the models was evaluated in Tucuxi using a local cohort of 69 neonates. Mean absolute error (MAE), relative bias (rBias) and relative root mean square error (rRMSE) were used to quantify the accuracy and precision of the predictive performance of each model for three different approaches: a priori, a posteriori, and Bayesian forecasting for the next course of therapy based on the previous course predictions. A PopPK model was considered clinically acceptable if rBias was between ± 20 and 95% confidence intervals included zero. RESULTS: A total of 25 PopPK models were identified and nine were considered suitable for further evaluation. The model of De Cock et al. 2014 was the only clinically acceptable model based on a priori [MAE 0.35 mg/L, rBias 0.8 % (95% confidence interval (CI) - 7.5, 9.1%), and rRMSE 8.9%], a posteriori [MAE 0.037 mg/L, rBias - 0.23% (95% CI - 1.3, 0.88%), and rRMSE 6.02%] and Bayesian forecasting for the next courses [MAE 0.89 mg/L, rBias 5.45% (95% CI - 8.2, 19.1%), and rRMSE 38.3%) approaches. CONCLUSIONS: The De Cock model was selected based on a comprehensive approach of model selection to individualize vancomycin dosing in our neonates.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Alrahahleh D, Thoma Y, Van Daele R, et al. Bayesian Vancomycin Model Selection for Therapeutic Drug Monitoring in Neonates. Clin Pharmacokinet. 2024. PMID: 38416322. doi:10.1007/s40262-024-01353-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。